Williams W L, Powers M, Wagman L D
City of Hope National Medical Center, Department of General Oncologic Surgery, Duarte, California 91010, USA.
J Natl Med Assoc. 1996 Jul;88(7):439-43.
A review of 20 cases of male breast cancer in 17 patients from 1959 to 1990 was performed. The median age at presentation was 53.3 years (range: 29 to 79). At the time of diagnosis, 30% (6) patients were stage I, 65% (13) stage II, and 5% (1) stage IV. Surgery was the initial form of therapy in all cases either as a radical mastectomy, modified radical mastectomy, or total mastectomy. The median disease-free survival was 4.8 years with a 5-year disease-free survival of 41%, and with a 5-year overall survival of 47%. Seven patients are alive with no evidence of disease, two are alive with disease, five have died of disease, and two died of other causes. Estrogen receptor (ER) and progesterone receptor (PR) assays were performed on the tumors of 10 patients, with 80% being ER positive and 70% PR positive. The median disease-free survival for ER positive patients was 6 months with a 5-year disease-free survival of 12.5%. The overall median survival for this group was 2.9 years with an overall 5-year survival of 25%. In this review there was a high percentage of patients who were ER positive. The positive receptor status had value in predicting decreased survival.
对1959年至1990年期间17例患者的20例男性乳腺癌病例进行了回顾性研究。就诊时的中位年龄为53.3岁（范围：29至79岁）。诊断时，30%（6例）患者为I期，65%（13例）为II期，5%（1例）为IV期。所有病例的初始治疗方式均为手术，包括根治性乳房切除术、改良根治性乳房切除术或全乳房切除术。中位无病生存期为4.8年，5年无病生存率为41%，5年总生存率为47%。7例患者存活且无疾病证据，2例患者存活但患有疾病，5例患者死于疾病，2例患者死于其他原因。对10例患者的肿瘤进行了雌激素受体（ER）和孕激素受体（PR）检测，其中80%为ER阳性，70%为PR阳性。ER阳性患者的中位无病生存期为6个月，5年无病生存率为12.5%。该组患者的总中位生存期为2.9年，5年总生存率为25%。在本回顾性研究中，ER阳性患者的比例较高。阳性受体状态对预测生存期缩短具有参考价值。
